Mycozyl AL

Manufacturer
PURETEK CORPORATION
Effective date
2023-10-17
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:53:58

Label at a glance#

ProductMycozyl AL
Active ingredientTOLNAFTATE
Label structure17 sections

Indications and uses

Mycozyl AL™ is effective in the treatment of most skin infections such as athlete's foot (tinea pedis) and ringworm (tinea corporis). Mycozyl AL™ has been designed to reach skin areas around and under the nails while it relives burning, cracking, scaling and discomfort which accompany these conditions. Mycozyl AL™ is an antifungal that works by preventing and eliminating the growth of fungus on fingers, toes and a...

Dosage and administration

• Clean the affected area with soap and warm water and dry thoroughly • Apply a thin layer of product over affected area twice daily (morning and night) paying special attention to the edges of the nail, cuticles and skin around the nails or as directed by a doctor • The brush applicator allows for easy application on skin around the nail and cuticle areas. • For athlete's foot, pay special attention to spaces bet...

Label contents#

Full prescribing information#

DESCRIPTION:

DESCRIPTION SECTION

Each gram of Mycozyl AL™ contains 10 mg of tolnaftate in a vehicle consisting of: Apple Cider Vinegar, Argania
Spinosa (Argan) Kernel Oil, Benzyl Alcohol, DMSO (Dimethyl Sulfoxide), Eucalyptus Globulus (Eucalyptus) Leaf
Oil, Glycerin, Laureth-4, Lavandula Angustifolia (Lavender) Oil, Melaleuca Alternifolia (Tea Tree) Leaf Oil, PEG-8,
DL-alpha-tocopheryl Acetate.


Chemically, tolnaftate molecular formula is C19H17NOS and molecular weight 314.5 and is represented by the
following structure formula:

StructureStructure

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

Tolnaftate has antifungal properties.

Pharmacokinetics:

PHARMACOKINETICS SECTION

Tolnaftate is only given topically, and there are no documented reports on its pharmacokinetics and systemic metabolism.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

Mycozyl AL™ is effective in the treatment of most skin infections such as athlete's foot (tinea pedis) and ringworm (tinea corporis). Mycozyl AL™ has been designed to reach skin areas around and under the nails while it relives burning, cracking, scaling and discomfort which accompany these conditions. Mycozyl AL™ is an antifungal that works by preventing and eliminating the growth of fungus on fingers, toes and around the nails. It eliminates and helps stop the spread of fungal infections on cuticles around nail edges and under the nail tips where reachable with applicator brush. Mycozyl AL™ cures and prevents fungal infections from coming back with daily use.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

Tolnaftate topically applied is not likely to affect drugs taken or injected, but many drugs can interact with each other.

PRECAUTIONS:

PRECAUTIONS SECTION

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Avoid contact with eyes, lips and mucous membranes.

WARNINGS:

WARNINGS AND PRECAUTIONS SECTION

For External Use Only. Not For Ophthalmic Use

General:

GENERAL PRECAUTIONS SECTION

Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider or pharmacist first.

Carcinogenesis, Mutagenesis, and Impairment of Fertility:

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of Tolnaftate.

Pregnancy:

PREGNANCY SECTION

Teratogenic effects - There is currently no published human data available on the teratogenic and fetotoxic effects of tolnaftate.

Nursing Mothers:

NURSING MOTHERS SECTION

Before using this medication while breastfeeding, it is recommended to consult with a healthcare professional.

Pediatric Use:

PEDIATRIC USE SECTION

Safety and effectiveness have not been established in pediatric patients less than 2 years of age.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

For athlete’s foot and ringworm - if irritation occurs or there is no improvement within 4 weeks.
For prevention of athlete’s foot – if irritation occurs, discontinue use and consult a doctor.

OVERDOSAGE:

OVERDOSAGE SECTION

(See PRECAUTIONS).

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

• Clean the affected area with soap and warm water and dry thoroughly
• Apply a thin layer of product over affected area twice daily (morning and night) paying special attention to the edges of the nail, cuticles and skin around the nails or as directed by a doctor
• The brush applicator allows for easy application on skin around the nail and cuticle areas.
• For athlete's foot, pay special attention to spaces between the toes, wear well-fitting,ventilated shoes, and change shoes and socks at least once daily.
• For athlete's foot and ringworm, use daily for 4 weeks.
• Supervise children in the use of this product.

11
Use under the direction of a licensed medical practitioner.
Call your doctor about side effects. To report side effects, call PureTek Corporation at
1-877-921-7873 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Mycozyl AL™ is supplied in:
10 mL glass bottle with a screw cap fitted with a brush applicator (NDC 59088-443-01).

Store at 20º-25ºC (68º-77ºF) [see USP Controlled Room Temperature]. Protect from freezing and excessive heat. Keep
container tightly closed.
Do not use if package is damaged. Keep out of reach of children.


Manufactured by:
PureTek Corporation
Panorama City, CA 91402
For questions or information
call toll-free: 877-921-7873

Mycozyl AL™

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LabelLabel

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
313423tolnaftate 1 % Topical SolutionPSN1
313423tolnaftate 10 MG/ML Topical SolutionSCD1
313423tolnaftate 1 % Topical SolutionSY1

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9869efd7-d6dd-0665-5b67-53adbe6ef15eProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
59088-443-01Mycozyl AL10 mL in 1 BOTTLELIQUID101

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
59088-443MYCOZYL AL (TOLNAFTATE) LIQUID [PURETEK CORPORATION]1Current NDC, Legacy NDC, 1 package rows20231018_07edd043-4ac4-b2de-e063-6394a90af25d.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
59088-443-03ML - Milliliter59088-443958250a3-49e2-439f-998a-bf21bf22ea5212021-08-05

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 13 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
59088-44359088-443-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Mycozyl ALTOLNAFTATEPureTek Corporationb82c9a8a-f6f1-dca6-e053-2995a90a47f92024-10-02WarningsExact identifier
ndc (product): 59088-443
Mycozyl ALTOLNAFTATEPURETEK CORPORATION07edd043-4ac4-b2de-e063-6394a90af25d2023-10-17Warnings, Adverse reactionsExact identifier
ndc (package): 59088-443-01
ndc (product): 59088-443
ndc11 (package): 59088044301
spl id: 07edd043-4ac5-b2de-e063-6394a90af25d
spl set id: 07edd043-4ac4-b2de-e063-6394a90af25d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.